Cellular Biomedicine (CBMG), a US-China biopharma, signed a lease to build a R&D facility in Maryland that will support early US trials of its CAR-T immunotherapy candidates. CBMG has already started China Phase I trials of its CAR-T treatment that was developed in its Shanghai and Beijing R&D facilities. The company focuses on immunotherapies for oncology indications and stem cell treatments for degenerative conditions. It said the US site will facilitate partnerships and innovation along with US development of its products.
